European Growth Companies With Insider Ownership Up To 30%
Amidst escalating geopolitical tensions and rising inflation concerns, European markets have recently faced headwinds, with the STOXX Europe 600 Index declining as energy prices surged. In such a challenging environment, growth companies with significant insider ownership can offer potential resilience and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.6% |
| MilDef Group (OM:MILDEF) | 10.3% | 31.1% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 12% | 103.8% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| CD Projekt Red (WSE:CDR) | 35.2% | 43.4% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 29.8% |
Let's explore several standout options from the results in the screener.
Avanza Bank Holding (OM:AZA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Avanza Bank Holding AB (publ) operates in Sweden, offering a range of savings, pension, and mortgage products with a market capitalization of SEK61.62 billion.
Operations: Avanza Bank Holding AB generates revenue primarily through its commercial operations, amounting to SEK5.38 billion.
Insider Ownership: 13.1%
Avanza Bank Holding shows promising growth potential with its earnings forecasted to grow at 7.68% annually, outpacing the Swedish market's 7.3%. Recent earnings results highlight a net income of SEK 785 million for Q2 2026, up from SEK 600 million a year ago. Despite trading below fair value estimates and having more insider purchases than sales recently, it faces challenges with an unstable dividend track record and no substantial insider buying in recent months.
- Take a closer look at Avanza Bank Holding's potential here in our earnings growth report.
- According our valuation report, there's an indication that Avanza Bank Holding's share price might be on the cheaper side.
Idorsia (SWX:IDIA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Idorsia Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for unmet medical needs across Switzerland, the United States, Japan, Europe, China, and Canada with a market cap of CHF1.31 billion.
Operations: The company generates revenue of CHF199.71 million from its activities in the discovery, development, and commercialization of drugs.
Insider Ownership: 30.1%
Idorsia Ltd demonstrates potential as a growth company with substantial insider ownership, despite challenges like negative shareholders' equity and recent shareholder dilution. The company's revenue is expected to grow at 18.8% annually, surpassing the Swiss market average. Recent strategic agreements, such as with Jamjoom Pharmaceuticals for QUVIVIQ distribution, and new executive appointments aim to enhance commercial performance and strategic execution. However, financial volatility persists with a significant net loss reported for H1 2026.
- Dive into the specifics of Idorsia here with our thorough growth forecast report.
- Our expertly prepared valuation report Idorsia implies its share price may be lower than expected.
Leonteq (SWX:LEON)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Leonteq AG is a company that offers derivative investment products and services across Switzerland, Europe, Asia, and internationally, with a market cap of CHF358.40 million.
Operations: The company's revenue segment includes brokerage services, generating CHF157.98 million.
Insider Ownership: 12.3%
Leonteq exhibits growth potential with substantial insider ownership, as evidenced by H21 Macro Ltd.'s acquisition of a 23.3% stake. The company's revenue is forecast to grow at 15.3% annually, outpacing the Swiss market average. Recent regulatory clarity from FINMA supports its business execution. Despite a volatile share price and debt concerns, Leonteq reported improved earnings for H1 2026, with net income rising to CHF 12.69 million from CHF 9.26 million year-on-year.
- Click here and access our complete growth analysis report to understand the dynamics of Leonteq.
- Upon reviewing our latest valuation report, Leonteq's share price might be too pessimistic.
Turning Ideas Into Actions
- Click through to start exploring the rest of the 210 Fast Growing European Companies With High Insider Ownership now.
- Looking For Alternative Opportunities? The end of cancer? These 34 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com